This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Szucs TD, Holm MV, Schwenkglenks M, Zhang Z, Weintraub WS, Burnier M, Erne P.Cost-effectiveness of eplerenone in patients with left ventricular dysfunction after myocardial infarction - an analysis of the EPHESUS Study from a Swiss perspective. Cardiovascular Drugs and Therapy 20: 193-204, No. 3, Jun 2006
Rights and permissions
About this article
Cite this article
Eplerenone “highly economically viable”. Pharmacoecon. Outcomes News 511, 4 (2006). https://doi.org/10.2165/00151234-200605110-00011
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200605110-00011